Stay updated on Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial
Sign up to get notified when there's something new on the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page.

Latest updates to the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page
- Check6 days agoChange DetectedPrimary outcome maintenance phase wording updated to 'Baseline through Week 48' from 'post-randomization through Week 48'.SummaryDifference0.3%

- Check13 days agoChange DetectedThe change is a minor revision update from v3.4.1 to v3.4.2; no substantive content changes are apparent. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedA new revision label v3.4.1 was added and the previous revision v3.4.0 was removed. This appears to be a cosmetic/versioning update that does not change study content or user-facing information on the page.SummaryDifference0.1%

- Check28 days agoChange DetectedAdded a Show glossary option and minor editorial updates to labeling and revision/version text (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 now displayed on the page (replacing v3.3.3). No changes to study content or navigation are apparent.SummaryDifference0.1%

- Check63 days agoChange DetectedLocations are consolidated under a single 'Locations' section listing the participating states, replacing the previous per-state location blocks. No changes to the actual sites, eligibility criteria, or study details.SummaryDifference1%

Stay in the know with updates to Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Oteseconazole for Recurrent Vaginal Candidiasis Clinical Trial page.